Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan

Table 2 Demographic and baseline characteristics of the study population

Characteristics	Total patients n = 268	Esomeprazole therapy n = 134	Lansoprazole therapy n = 134
Age (yr) (mean ± SD) range	61 ± 14 23-92	61 ± 13 25-84	61 ± 14 23-92
Sex, male, %	186, 69%	92, 69%	94, 70%
BMI (mean ± SD)	22.9 ± 3.5	22.7 ± 3.5	23.0 ± 3.5
Alcohol1, n, (%)	119, 44%	54, 42%	65, 49%
Smoking (%)	75, 28%	37, 28%	38, 28%
Underlying diseases
Hypertension, n, %	69, 26%	35, 26%	34, 25%
Diabetes mellitus, n, %	35, 13%	18, 13%	17, 13%
Lipid disorder, n, %	31, 12%	12, 9%	19, 14%
Chronic lung disease, n, %	7, 3%	4, 3%	3, 2%
Disease for H. pylori eradication
Gastric ulcer, n, %	163, 61%	82, 61%	81, 61%
Duodenal ulcer, n, %	59, 22%	29, 22%	30, 22%
Gastroduodenal ulcer, n, %	7, 3%	5, 4%	2, 1.5%
Gastric MALT lymphoma, n, %	2, 0.7%	0, 0%	2, 1.5%
ITP, n, %	1, 0.4%	1, 0.8%	0, 0%
EGC after endoscopic therapy, n, %	36, 13%	17, 13%	19, 14%
Therapy and test for H. pylori eradication
Clarithromycin 400 mg/800 mg per day	28/233	12/118	16/115
Urea breath test/stool antigen test/others	230/17/4	113/8/3	117/9/1
Compliance2
Good, n, %	226 (84%)	110 (82%)	116 (87%)

¹Alcohol habit was defined as drinking more than twice a week, consumption of more than 15 g of ethanol on each occasion in this study, 100 (%) If compliance was more than 75%, it graded as good;

²Compliance = actual number of internal use/14 (total number of internal use/7 d). BMI: Body mass index; MALT: Mucosa associated lymphoid tissue; ITP: Idiopathic thrombocytopenic purpura; EGC: Early gastric cancer; H. pylori: Helicobacter pylori.